Selected stock price target news of the day - July 21st, 2025

By: Matthew Otto

Charles Schwab Q2 Profit Rises 60% on Trading and Asset Growth

Charles Schwab reported second-quarter 2025 earnings per share (EPS) of $1.14, exceeding the analyst consensus estimate of $1.09 by $0.05. Revenue for the quarter totaled $5.85 billion, slightly above the expected $5.7 billion and marking a 25% increase from $4.69 billion in the same period last year.

Net income rose to $2.13 billion, up 60% from $1.33 billion in Q2 2024. Trading revenue grew to $952 million from $777 million, while asset management and administration fees increased 14% to $1.6 billion. Net interest margin expanded to 2.65%, supported by lower funding costs and a recovery in securities lending activity.

Schwab opened 1.1 million new brokerage accounts during the quarter, up 11% year-over-year, bringing total active brokerage accounts to 37.5 million. Core net new assets reached $80.3 billion, a 31% increase compared to the year-ago period, contributing to a 14% rise in total client assets to $10.76 trillion. Margin balances stood at $83.4 billion, and daily average trading volume rose 38% to 7.6 million. Schwab also reduced its bank supplemental funding by $10.4 billion, ending the quarter at $27.7 billion.

Analysts Raise Price Targets Following Q2 Results

Truist Securities analyst David Smith maintained a Buy rating while boosting the price target from $100 to $107.
JMP Securities analyst Devin Ryan reiterated a Market Outperform rating and lifted the price target from $106 to $110.
BofA Securities analyst Craig Siegenthaler kept an Underperform rating but nudged the price target upward from $83 to $84.
Keefe, Bruyette & Woods analyst Kyle Voigt maintained an Outperform rating and increased the price target from $102 to $108.

Which Analyst has the best track record to show on SCHW?

Analyst Patrick O’shaughnessy (RAYMOND JAMES) currently has the highest performing score on SCHW with 9/10 (90%) price target fulfillment ratio. His price targets carry an average of $6.68 (7.24%) potential upside. Charles Schwab stock price reaches these price targets on average within 248 days.

Comerica Reports Lower Q2 2025 Earnings, Beats EPS Expectations

Comerica reported its financial results for the second quarter of 2025 posting a revenue of $849 million, slightly above the consensus estimate of $843.63 million. Though it is down 2.3% from $870.5 million in the same quarter last year.

Net income declined 6.5% year-over-year to $187 million, while profit margin dropped to 23%, compared to 24% in Q2 2024. Earnings per share (EPS) came in at $1.43, exceeding analyst expectations by $0.18, despite declining from $1.5 in the prior-year period. Total assets stood at $78 billion as of June 30, 2025.

According to company guidance, revenue is projected to grow at an average rate of 3.4% annually over the next three years, compared to a 7.6% average growth forecast for the U.S. banking industry.

Analysts Adjust Price Targets Following Q2 Results

Stephens & Co. analyst Terry McEvoy maintained an Equal-Weight rating and raised the price target from $61 to $68.
Keefe, Bruyette & Woods analyst Christopher Mcgratty kept an Outperform rating while lifting the price target from $69 to $73.
DA Davidson analyst Peter Winter increased the price target from $56 to $60.
Citi analyst Keith Horowitz reiterated a Neutral rating and increased the price target from $61 to $69.

Which Analyst has the best track record to show on CMA?

Analyst Manan Gosalia (MORGAN STANLEY) currently has the highest performing score on CMA with 13/16 (81.25%) price target fulfillment ratio. His price targets carry an average of $3.72 (7.25%) potential upside. Comerica stock price reaches these price targets on average within 61 days.

FDA Scrutiny Puts Sarepta’s Gene Therapy in Jeopardy Following Patient Deaths

Sarepta Therapeutics is under increased regulatory scrutiny after disclosing three patient deaths tied to its gene therapy programs—two involving its approved treatment, Elevidys, and one related to a separate experimental therapy. The U.S. Food and Drug Administration (FDA) is expected to ask Sarepta to voluntarily halt all shipments of Elevidys, although the company stated it has not received an official

The FDA has been investigating the liver failure deaths of two teenage patients who received Elevidys, a therapy accounting for more than 50% of Sarepta’s total net product revenue. A third death occurred during a Phase 1 trial of another gene therapy candidate. Elevidys was granted conditional approval in June 2023 and has since been expanded to include ambulatory and non-ambulatory patients aged 4 and older.

Duchenne muscular dystrophy (DMD), the condition Elevidys is intended to treat, affects approximately 1 in every 3,500 to 5,000 male births globally. In the U.S., this translates to roughly 10,000 to 12,000 individuals living with DMD. Sarepta previously estimated that Elevidys could potentially benefit around 4,000 to 6,000 eligible patients in the U.S. alone—primarily boys between the ages of 4 and 18 who meet functional criteria.

Families such as that of Jennifer Handt, whose son participated in a late-stage trial and experienced noticeable improvement, continue to advocate for access to the drug. However, analysts like BMO’s Kostas Biliouris highlight that Elevidys lacks the clearly demonstrated benefits seen in other gene therapies, such as Novartis’ Zolgensma, making the recent fatalities particularly significant.

Analysts Cut Ratings and Price Targets as Elevidys Faces FDA Pressure

Leerink Swann analyst Mani Foroohar downgraded from Outperform to Market Perform and the price target from $45 to $10.
JP Morgan analyst Anupam Rama maintained an Overweight rating but lowered the price target from $28 to $20.
Needham analyst Gil Blum downgrades from Hold to Underperform.

Which Analyst has the best track record to show on SRPT?

Analyst Mitchell Kapoor (HC WAINWRIGHT) currently has the highest performing score on SRPT with 8/14 (57.14%) price target fulfillment ratio. His price targets carry an average of $-7.46 (-42.73%) potential downside. Sarepta Therapeutics stock price reaches these price targets on average within 55 days.